We mined AstraZeneca’s partnerships, investments, and acquisitions to discern the company's strategic priorities.
By 2030, AstraZeneca wants to be a top-3 pharma player in each of its 5 focus areas: oncology; cardiovascular, renal, and metabolism; respiratory and immunology; vaccines and immunotherapies; and rare diseases.
To reach that goal, the pharma giant is investing internally — it has 178 projects in the pipeline and spent nearly $11B on R&D last year, up 12% from 2022 — as well as looking to emerging technologies that can help it fire on all cylinders.
AstraZeneca has been strategically partnering with companies offering AI drug discovery, diagnostics, and real-world data to help offset some of the cost of drug development and speed up the process. For example, it signed a $247M deal with Absci in December 2023 to develop generative AI-designed antibody therapies for cancer.
Using CB Insights data, we uncovered 4 strategic priorities highlighted by AstraZeneca’s business relationships with tech companies since 2022. We then categorized these companies by their relationships with AstraZeneca across these priorities:
- AI drug & antibody discovery
- Diagnostics
- Gene editing
- Real-world data
Want to see more research? Join a demo of the CB Insights platform.
If you’re already a customer, log in here.
